Company intelligence / Profile preview
Illexcor Therapeutics
Richmond, Virginia, United Statesillexcor.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Developing ILX002, a first-in-class oral drug designed to bind to Hemoglobin S and directly block polymerization and sickling. Currently in preclinical development with plans to enter clinical trials later in 2025.
- Therapeutic areas
- Hematology
- Modalities
- Small molecules (oral therapies)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Zynext Ventures (investment partner)
Beyond the preview
Go deeper on Illexcor Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Illexcor Therapeutics.